Reducing suboptimal prescribing of glucagon-like peptide mimetics in type 2 diabetes | Correspondence

A formulary update and development of key resources in collaboration with primary and secondary care colleagues ran parallel to the patient-centred reviews.

All but two practices from across both CCGs (n=44) undertook the project and agreed an action plan with their MM pharmacist.

In total, 850 patient records were reviewed by the MM team. Half were considered suitable for a face-to-face clinician review, with the aim of stopping the GLP-1 mimetic, where appropriate, and optimising medicines for diabetes.

In 93% (n=396) of patients, recommendations to optimise therapy were implemented, which generated significant financial savings across both CCGs. The CCGs demonstrated reduced growth of GLP-1 mimetic prescribing compared with national growth.

Owing to the variation in baseline prescribing of these agents, rates of change varied between practices. Some practices achieved rates of change of 20%, while others achieved significantly higher rates of change (over 75%). It was proposed that GP practices with small patient numbers at baseline may have the least potential for change; however, in practice, there were no data to support any such correlation.

Leave a Reply

Your email address will not be published. Required fields are marked *